Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leukine vs Neupogen in Urothelial Cancer
NCT00237575Phase 3Terminated
- Sponsor
- University of Kentucky
- Start
- Nov 2005
- Primary completion
- Mar 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sargramostim in neutropenia (2 arms), sponsored by University of Kentucky. Primary endpoints: Incidence of grade 3 and 4 neutropenia and Safety of Leukine & Neupogen. Started Nov 2005; status: terminated.
02
Drugs
sargramostim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT00237575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00237575.